We advocate for compounding pharmacies and facilities on a range of state and federal issues affecting patient access to compounded medications. We represent pharmacists and technicians in both traditional 503A compounding pharmacies and 503B outsourcing facilities, as well as prescribers, patients, educators, and suppliers. We’re 5,000 members strong and growing.
It’s not hyperbole to say that the ruling in Zyla Life Sciences v. Wells Pharma is profoundly troubling for pharmacy compounding.
Potential pharma tariffs are more complex than you might think. One article goes into the nitty-gritty.
We’ve put together six short videos that provide crystal clear explanations of how compounding actually works — share them!
The FDA held a “listening session” with APC, where the agency sat down to hear our perspective — and concerns — on a range of compounding issues.
A Texas bill would impose prescription labeling requirements that pharmacies are prohibited from making under federal law.
.png?width=410&height=320&name=image-container%20(1).png)
.png?width=410&height=320&name=image-container%20(2).png)
.png?width=411&height=320&name=image-container%20(3).png)
.png?width=410&height=320&name=image-container%20(4).png)
.png)
.png?width=17&height=16&name=folder%20(1).png){kind=small}
%20Pharma-GS.png)
